Join the Endometrial Cancer group to help and get support from people like you.
Endometrial Cancer News
Related terms: Cancer, Endometrial, Cancer, Uterine, Endometrial Adenocarcinoma, Endometrial Carcinoma, Uterine Adenocarcinoma, Uterine Cancer, Uterine corpus cancer
Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer
WEDNESDAY, Aug. 14, 2024 – For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate, shows...
FDA Expands Jemperli (dostarlimab-gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
Philadelphia, PA – August 01 2024 GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and...
Many Women Don't Know This Warning Sign of Endometrial Cancer
FRIDAY, Aug. 2, 2024 – Too many women don’t know a key warning sign of endometrial cancer, the most common cancer of the female reproductive organs, a new study shows. More than one-third (37%) of w...
Transvaginal Ultrasound Triage Strategy for Endometrial Cancer Not Reliable for Black Women at Risk
WEDNESDAY, July 10, 2024 – For Black adults at risk for endometrial cancer (EC), a transvaginal ultrasonography triage strategy is not reliable, according to a study published online June 27 in JAMA...
Ultrasound May Be Unreliable in Spotting Endometrial Cancer in Black Women
TUESDAY, July 2, 2024 – Ultrasound cannot reliably rule out endometrial cancer in Black women given how readings are now assessed, a new study argues. Transvaginal ultrasound is commonly used to...
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
FRIDAY, June 21, 2024 – The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Breast Cancer Survivors Face Higher Odds for Second Cancer
THURSDAY, April 25, 2024 – People lucky enough to survive a breast cancer may still face heightened risks for other cancers later, a new study shows. The researchers stressed that the absolute risk...
Today's Young Adults Are Aging Faster, and That Might Help Spur Cancers
MONDAY, April 8, 2024 – Younger generations are aging more rapidly, and this could be leading to an increased risk of cancer, a new study says. People born in or after 1965 are 17% more likely to be...
Rucaparib Could Extend Survival for Uterine Cancer Patients
FRIDAY, March 22, 2024 – An already approved cancer drug could be an effective treatment for women with advanced, recurring uterine cancer, a new clinical trial shows. Rucaparib, which belongs to a...
High-Tech Screening Might Spot More Cancer Patients Who'd Benefit From Immunotherapy
FRIDAY, Dec. 29, 2023 – More patients could benefit from immunotherapy, a highly effective treatment for some cancers, new research suggests. Revising current testing guidelines so that a more...
White Women Overrepresented in Gynecologic Cancer Trials
TUESDAY, Dec. 12, 2023 – White women are disproportionately represented in clinical trials for gynecologic cancers, according to a study published online Dec. 7 in JAMA Network Open. Wafa Khadraoui, ...
Moderate, Heavy Use of Chemical Hair Relaxer Linked to Uterine Cancer
THURSDAY, Nov. 2, 2023 – Among postmenopausal Black women, moderate and heavy use of chemical hair relaxers is associated with an increased risk for uterine cancer, according to a study published...
Use of Hair Relaxers Raises Women's Odds for Uterine Cancer
FRIDAY, Oct. 13, 2023 – Older Black women who use chemical hair relaxers may be more likely to develop uterine cancer, new research suggests. Specifically, postmenopausal Black women who reported...
Jemperli (dostarlimab-gxly) Plus Chemotherapy Approved in the US for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...